Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins.

Jacobs JFM, Turner KA, Graziani MS, Frinack JL, Ettore MW, Tate JR, Booth RA, McCudden CR, Keren DF, Delgado JC, Zemtsovskaja G, Fullinfaw RO, Caldini A, de Malmanche T, Katakouzinos K, Burke M, Palladini G, Altinier S, Zaninotto M, Righetti G, Melki MT, Bell S, Willrich MAV.

Clin Chem Lab Med. 2020 Jan 15. pii: /j/cclm.ahead-of-print/cclm-2019-1105/cclm-2019-1105.xml. doi: 10.1515/cclm-2019-1105. [Epub ahead of print]

PMID:
31940285
2.

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.

Turner KA, Frinack JL, Ettore MW, Tate JR, Graziani MS, Jacobs JFM, Booth RA, McCudden CR, Keren DF, Delgado JC, Zemtsovskaja G, Fullinfaw RO, Caldini A, de Malmanche T, Katakouzinos K, Burke M, Palladini G, Altinier S, Zaninotto M, Righetti G, Melki MT, Bell S, Willrich MAV.

Clin Chem Lab Med. 2020 Jan 15. pii: /j/cclm.ahead-of-print/cclm-2019-1104/cclm-2019-1104.xml. doi: 10.1515/cclm-2019-1104. [Epub ahead of print]

PMID:
31940284
3.

Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.

Maritan M, Romeo M, Oberti L, Sormanni P, Tasaki M, Russo R, Ambrosetti A, Motta P, Rognoni P, Mazzini G, Barbiroli A, Palladini G, Vendruscolo M, Diomede L, Bolognesi M, Merlini G, Lavatelli F, Ricagno S.

J Mol Biol. 2019 Dec 24. pii: S0022-2836(19)30715-6. doi: 10.1016/j.jmb.2019.12.015. [Epub ahead of print]

PMID:
31874151
4.

Amyloidosis in Heart Failure.

Ihne S, Morbach C, Obici L, Palladini G, Störk S.

Curr Heart Fail Rep. 2019 Dec;16(6):285-303. doi: 10.1007/s11897-019-00446-x. Review.

PMID:
31782077
5.

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.

Basset M, Defrancesco I, Milani P, Nuvolone M, Rattotti S, Foli A, Mangiacavalli S, Varettoni M, Benvenuti P, Cartia CS, Paulli M, Merlini G, Arcaini L, Palladini G.

Blood. 2020 Jan 23;135(4):293-296. doi: 10.1182/blood.2019002762. No abstract available.

PMID:
31714952
6.

Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance.

Chattopadhyay S, Thomsen H, Weinhold N, Meziane I, Huhn S, da Silva Filho MI, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2019 Nov 6. doi: 10.1038/s41375-019-0619-1. [Epub ahead of print] No abstract available.

PMID:
31695157
7.

An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.

Milani P, Mussinelli R, Perlini S, Palladini G, Obici L.

Expert Opin Pharmacother. 2019 Dec;20(18):2223-2228. doi: 10.1080/14656566.2019.1671352. Epub 2019 Sep 30.

PMID:
31566422
8.

Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations.

Maritan M, Ambrosetti A, Oberti L, Barbiroli A, Diomede L, Romeo M, Lavatelli F, Sormanni P, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Amyloid. 2019;26(sup1):105-106. doi: 10.1080/13506129.2019.1583185. No abstract available.

9.

The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis.

Oberti L, Maritan M, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Amyloid. 2019;26(sup1):107-108. doi: 10.1080/13506129.2019.1583187. No abstract available.

10.

Predicting survival in light chain amyloidosis.

Palladini G, Milani P, Merlini G.

Haematologica. 2019 Jul;104(7):1294-1296. doi: 10.3324/haematol.2019.218859. No abstract available.

11.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F.

Blood. 2019 Jul 18;134(3):320-323. doi: 10.1182/blood.2019000420. Epub 2019 Jun 6. No abstract available.

PMID:
31171502
12.

Parkinsonism and dysautonomia: Multiple system atrophy?

Albanese A, Cocco A, Milani P, Lalli S, Palladini G.

Parkinsonism Relat Disord. 2019 May 3. pii: S1353-8020(19)30226-3. doi: 10.1016/j.parkreldis.2019.05.005. [Epub ahead of print] No abstract available.

PMID:
31097298
13.

Fatty Acid Desaturase Involvement in Non-Alcoholic Fatty Liver Disease Rat Models: Oxidative Stress Versus Metalloproteinases.

Palladini G, Di Pasqua LG, Berardo C, Siciliano V, Richelmi P, Mannucci B, Croce AC, Rizzo V, Perlini S, Vairetti M, Ferrigno A.

Nutrients. 2019 Apr 8;11(4). pii: E799. doi: 10.3390/nu11040799.

14.

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.

Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, Palladini G, Merlini G, Ricagno S, Bolognesi M.

Nat Commun. 2019 Mar 20;10(1):1269. doi: 10.1038/s41467-019-09133-w.

15.

Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress.

Palladini G, Di Pasqua LG, Berardo C, Siciliano V, Richelmi P, Perlini S, Ferrigno A, Vairetti M.

Can J Gastroenterol Hepatol. 2019 Feb 3;2019:5413461. doi: 10.1155/2019/5413461. eCollection 2019.

16.

ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis.

Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, Nuvolone M, Palladini G, Merlini G, Lavatelli F, Natalello A.

Anal Chem. 2019 Feb 19;91(4):2894-2900. doi: 10.1021/acs.analchem.8b05008. Epub 2019 Feb 4.

PMID:
30676723
17.

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.

Palladini G, Merlini G.

Blood Adv. 2019 Jan 22;3(2):212-215. doi: 10.1182/bloodadvances.2018021253. No abstract available.

18.

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options.

Moutafi M, Ziogas DC, Michopoulos S, Bagratuni T, Vasileiou V, Verga L, Merlini G, Palladini G, Matsouka C, Dimopoulos MA, Kastritis E.

BMC Med Genet. 2019 Jan 21;20(1):23. doi: 10.1186/s12881-019-0755-5.

19.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
20.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
21.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.

22.

Novel Therapies in Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. eCollection 2018 May. Review.

23.

Management of the elderly patient with AL amyloidosis.

Nuvolone M, Milani P, Palladini G, Merlini G.

Eur J Intern Med. 2018 Dec;58:48-56. doi: 10.1016/j.ejim.2018.05.004. Epub 2018 May 23. Review.

PMID:
29801808
24.

Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018022. doi: 10.4084/MJHID.2018.022. eCollection 2018. Review.

25.

The elusive pathogenesis of Schnitzler syndrome.

Palladini G, Merlini G.

Blood. 2018 Mar 1;131(9):944-946. doi: 10.1182/blood-2018-01-824862. No abstract available.

PMID:
29496698
26.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

PMID:
29386197
27.

New concepts in the treatment and diagnosis of amyloidosis.

Milani P, Palladini G, Merlini G.

Expert Rev Hematol. 2018 Feb;11(2):117-127. doi: 10.1080/17474086.2018.1424534. Epub 2018 Jan 10. Review.

PMID:
29307226
28.

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.

Oberti L, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Maritan M, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Sci Rep. 2017 Dec 1;7(1):16809. doi: 10.1038/s41598-017-16953-7.

29.

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.

Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F.

Sci Rep. 2017 Nov 15;7(1):15661. doi: 10.1038/s41598-017-15424-3.

30.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.

PMID:
29101236
31.

The lung in amyloidosis.

Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170046. doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30. Review.

32.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

33.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

34.

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G.

Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467. Epub 2017 May 25.

PMID:
28546143
35.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Lavatelli F, Nuvolone M, Ferraro G, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517. No abstract available.

PMID:
28434343
36.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.

Basset M, Milani P, Russo F, Lavatelli F, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):60-61. doi: 10.1080/13506129.2017.1292901. No abstract available.

PMID:
28434342
37.

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G.

Amyloid. 2017 Mar;24(sup1):68-69. doi: 10.1080/13506129.2017.1293644. No abstract available.

PMID:
28434326
38.

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):66-67. doi: 10.1080/13506129.2017.1293643. No abstract available.

PMID:
28434323
39.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
40.

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G.

Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916. No abstract available.

PMID:
28434293
41.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
42.

Regulated expression of amyloidogenic immunoglobulin light chains in mice.

Nuvolone M, Sorce S, Pelczar P, Rushing E, Lavatelli F, Rognoni P, Valentini V, Palladini G, Merlini G, Aguzzi A.

Amyloid. 2017 Mar;24(sup1):52-53. doi: 10.1080/13506129.2017.1289914. No abstract available.

PMID:
28434289
43.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.

Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G.

Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743. doi: 10.1515/cclm-2016-1024.

PMID:
28343171
44.

Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Diomede L, Romeo M, Rognoni P, Beeg M, Foray C, Ghibaudi E, Palladini G, Cherny RA, Verga L, Capello GL, Perfetti V, Fiordaliso F, Merlini G, Salmona M.

Antioxid Redox Signal. 2017 Sep 20;27(9):567-582. doi: 10.1089/ars.2016.6848. Epub 2017 Mar 3.

45.

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.

Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S.

Blood. 2017 Apr 13;129(15):2132-2142. doi: 10.1182/blood-2016-08-730978. Epub 2017 Jan 27.

PMID:
28130214
46.

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2017 Apr 13;129(15):2120-2123. doi: 10.1182/blood-2016-12-756528. Epub 2017 Jan 27.

PMID:
28130212
47.

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.

Leukemia. 2017 Aug;31(8):1735-1742. doi: 10.1038/leu.2016.387. Epub 2016 Dec 27.

PMID:
28025584
48.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.

Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21.

PMID:
27872060
49.

N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.

Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A.

Am J Hematol. 2016 Nov;91(11):1129-1134. doi: 10.1002/ajh.24532. Epub 2016 Aug 29.

50.

Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.

Milani P, Palladini G, Merlini G.

Scand J Clin Lab Invest Suppl. 2016;245:S113-8. doi: 10.1080/00365513.2016.1210337. Epub 2016 Jul 28. Review.

PMID:
27467897

Supplemental Content

Loading ...
Support Center